Korro Bio, Inc.

We are pleased to share a review article published in American College of Chest Physicians’ CHEST® Journal highlighting the merits of RNA editing in Alpha-1 Antitrypsin Deficiency (#AATD) and its potential for treatment for both liver and lung disease. Read the full article here: https://lnkd.in/eP2yDxpW #Alpha1 #Alpha1AntitrypsinDeficiency #RNAEditing #GeneticMedicine

Thank you, Luke Timmerman, for a great conversation with our CEO, Ram Aiyar, on The Long Run podcast. The discussion covered Ram’s career journey spanning science, pharma, venture capital and startups, and Korro’s focus on developing innovative RNA therapies for rare and highly prevalent diseases. Listen to the full podcast with this link: https://lnkd.in/e_HPhknZ #RNAEditing #GeneticMedicine

Institutional investors are invited to join us next Tuesday, January 14th, for an exclusive series of fireside chats with the leadership teams of Absci, Korro Bio, Inc., and Neumora. These insightful sessions, led by our covering research analysts, will provide a deep dive into each company's latest innovations and strategic vision.   Food will be provided, with limited seats available. For more information and to RSVP, please email corporateaccess@hcwco.com.   #JPM2025 #JPM25 #JPMHealthcare

Korro Bio is pleased to provide a pipeline update, and to announce the initiation of dosing in our REWRITE study investigating KRRO-110 as a potential treatment for Alpha-1 Antitrypsin Deficiency (#AATD).   REWRITE is a two-part single and multiple dose-escalating study that will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of KRRO-110, with an interim readout expected in the second half of 2025.   Read the full release: https://lnkd.in/e_cX2USH #Alpha1 #Alpha1AntitrypsinDeficiency #RNAEditing #GeneticMedicine

We’re pleased to announce that Korro Bio will be attending the 43rd Annual J.P. Morgan Healthcare Conference. Our CEO, Ram Aiyar, Ph.D., will be presenting on Monday, January 13, at 3:45 PM PT / 6:45 PM ET at the Westin St. Francis in San Francisco, to share an update on Korro's progress. Listen to the presentation via a live webcast: https://lnkd.in/g4n4jJqk   Our CFO, Vineet Agarwal, and CMO, Kemi Olugemo, MD, FAAN, will also be participating at the conference.   #KorroBio #JPM2025 #RNA #RNAEditing #Biotech #GeneticMedicine #HealthcareInnovation

As the year wraps up, we look forward to taking some time to recharge and prepare for 2025!   Next year, we’ll continue our mission to develop innovative RNA therapies to improve the lives of those facing debilitating and life-threatening diseases. We’re excited for what’s to come and grateful for your continued support.   Wishing you a joyful and restful holiday season!

The #KorroKrew was honored to join our friends and partners in the Alpha-1 community and Alpha-1 Foundation for the 2024 A1F Virtual Walk! Thanks to everyone who put together this fun and important event raising awareness and funds for Alpha-1 Antitrypsin Deficiency (#AATD).   Check out the impact we made together in the recap video: https://lnkd.in/eb8cu_ND #Alpha1Awareness #A1FWalk #Alpha1Foundation

What do cephalopods – such as squids and octopus – have in common with the discovery of new medicines? A documentary by students at MIT Graduate Program in Science Writing has an answer: RNA editing.   Inspired by cephalopods’ ability to edit their RNA at any given moment, scientists at Korro Bio are working to harness the RNA editing technology to develop medicines for both rare and highly prevalent diseases. The approach aims to correct the genetic information itself instead of focusing on addressing the symptoms. Learn more about how the approach works in this short film: https://lnkd.in/g-G998P8 #RNAediting #RNAresearch #GeneEditing #KorroBio

Attending the Oppenheimer Movers in Rare Disease Summit on Thursday?   Don’t miss our CEO & President, Ram Aiyar, Ph.D., at 3:40 PM ET participate in the panel discussion “Recent Progress in RNA Editing.” #RNAEditing #GeneticMedicine #OppenheimerAndCo Oppenheimer & Co. Inc.

Please join us in welcoming Christina Broomes, MBA, to Korro Bio as Vice President, Technical Operations!  With over 20 years of experience in biotechnology, Christina specializes in clinical and commercial manufacturing, GMP facility development, and CMC strategy. Her superpower is leading teams to successfully deliver genetic medicines to patients, and we’re excited to have her on the #KorroKrew to do just that! #KorroBio #TechnicalOperations